Please login to the form below

Not currently logged in
Email:
Password:

Watson appoints management consultant to oversee Actavis acquisition

Marc Lehnen will lead the company's new global integration management office

Watson appoints management consultant to oversee Actavis acquisition

Watson has appointed Marc Lehnen to lead its new global integration management office, set up to support its €4.3bn acquisition of Swiss generics company Actavis.

Lehnen will join the US company on July 1 from McKinsey, where he spent 10 years, during which time he served in the management consultants' European healthcare practice.

Taking up the newly-created position of senior vice president of global integration management at Watson Lehnen's role will be to focus on planning and implementing the integration of Actavis.

Lehnen will be involved in integration planning before his official July start-date, and will report to Actavis president and CEO Paul Bisaro.

“Marc has years of experience in the generic industry and knows our culture and way of operating.  Marc will be charged with identifying members of senior management across the organisations to support the global integration of the two companies, and developing and executing the strategies necessary to bring Watson and Actavis together following the close later this year,” Bisaro said.

Watson expects the Actavis deal to close in the fourth quarter of 2012, which it says will make it the third largest generics company in the world, with more than 17,000 employees and pro forma revenues of around €6bn.

11th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics